UB Paderborn / Katalog / Suche / in CDI

Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma

Nature communications, 2021-05, Vol.12 (1), p.2877-17, Article 2877

2021

Volltextzugriff (PDF)

Checkpoint inhibitors in hematological malignancies

Journal of hematology and oncology, 2017-05, Vol.10 (1), p.103-103, Article 103

2017

Volltextzugriff (PDF)

EBV-positive diffuse large B-cell lymphoma of the elderly

Blood, 2013-07, Vol.122 (3), p.328-340

2013

Volltextzugriff (PDF)

Utility of p53 immunohistochemistry as a surrogate for sequencing in myeloid neoplasms: A tale of caution

American journal of hematology, 2024-02, Vol.99 (2), p.329-330

2024

Volltextzugriff (PDF)

EBV-driven B-cell lymphoproliferative disorders: from biology, classification and differential diagnosis to clinical management

Experimental & molecular medicine, 2015-01, Vol.47 (1), p.e132-e132

2015

Volltextzugriff (PDF)

Long‐term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib

British journal of haematology, 2018-11, Vol.183 (4), p.578-587

2018

Volltextzugriff (PDF)

High-grade B-cell lymphomas with TdT expression: a diagnostic and classification dilemma

Modern pathology, 2019-01, Vol.32 (1), p.48-58

2019

Volltextzugriff (PDF)

Aberrant Activation of the Hedgehog Signaling Pathway in Malignant Hematological Neoplasms

The American journal of pathology, 2012, Vol.180 (1), p.2-11

2012

Volltextzugriff (PDF)

ETNK1 mutation occurs in a wide spectrum of myeloid neoplasms and is not specific for atypical chronic myeloid leukemia

Cancer, 2023-03, Vol.129 (6), p.878-889

2023

Volltextzugriff (PDF)

Mantle cell lymphoma involving tonsils: a clinicopathologic study of 83 cases

Human pathology, 2021-12, Vol.118, p.60-68

2021

Volltextzugriff (PDF)

Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia

Haematologica (Roma), 2019-02, Vol.104 (2), p.305

2019

Volltextzugriff (PDF)

Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) ‐ outcomes and mutation profile from venetoclax resistant MCL patients

American journal of hematology, 2020-06, Vol.95 (6), p.623-629

2020

Volltextzugriff (PDF)

Validation of a 12‐color flow cytometry assay for acute myeloid leukemia minimal/measurable residual disease detection

Cytometry. Part B, Clinical cytometry, 2023-09, Vol.104 (5), p.356-366

2023

Volltextzugriff (PDF)

CD30 expression is frequently decreased in relapsed classic Hodgkin lymphoma after anti‐CD30 CAR T‐cell therapy

Histopathology, 2023-07, Vol.83 (1), p.143-148

2023

Volltextzugriff (PDF)

Prevalence and Clinical Implications of Epstein―Barr Virus Infection in De Novo Diffuse Large B-Cell Lymphoma in Western Countries

Clinical cancer research, 2014-05, Vol.20 (9), p.2338-2349

2014

Volltextzugriff (PDF)

Genomic and clinical characterization of B/T mixed phenotype acute leukemia reveals recurrent features and T‐ALL like mutations

American journal of hematology, 2018-11, Vol.93 (11), p.1358-1367

2018

Volltextzugriff (PDF)

Acquired WT1 mutations contribute to relapse of NPM1-mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplant

Bone marrow transplantation (Basingstoke), 2022-03, Vol.57 (3), p.370-376

2022

Volltextzugriff (PDF)

Mantle cell lymphoma with chronic lymphocytic leukemia-like features: a diagnostic mimic and pitfall

Human pathology, 2022-01, Vol.119, p.59-68

2022

Volltextzugriff (PDF)

EZH2 expression is associated with inferior overall survival in mantle cell lymphoma

Modern pathology, 2021-12, Vol.34 (12), p.2183-2191

2021

Volltextzugriff (PDF)

Acute Myeloid Leukemia and Myelodysplastic Syndromes After Radiation Therapy Are Similar to De Novo Disease and Differ From Other Therapy-Related Myeloid Neoplasms

Journal of clinical oncology, 2012-07, Vol.30 (19), p.2340-2347

2012

Volltextzugriff (PDF)

Clinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology group

Modern pathology, 2019-09, Vol.32 (9), p.1373-1385

2019

Volltextzugriff (PDF)

Myelodysplastic syndromes with no somatic mutations detected by next‐generation sequencing display similar features to myelodysplastic syndromes with detectable mutations

American journal of hematology, 2021-11, Vol.96 (11), p.E420-E423

2021

Volltextzugriff (PDF)

Clinical, immunophenotypic and genomic findings of NK lymphoblastic leukemia: a study from the Bone Marrow Pathology Group

Modern pathology, 2021-07, Vol.34 (7), p.1358-1366

2021

Volltextzugriff (PDF)

Chronic myeloid neoplasms harboring concomitant mutations in myeloproliferative neoplasm driver genes (JAK2/MPL/CALR) and SF3B1

Modern pathology, 2021-01, Vol.34 (1), p.20-31

2021

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma

Checkpoint inhibitors in hematological malignancies

EBV-positive diffuse large B-cell lymphoma of the elderly

Utility of p53 immunohistochemistry as a surrogate for sequencing in myeloid neoplasms: A tale of caution

EBV-driven B-cell lymphoproliferative disorders: from biology, classification and differential diagnosis to clinical management

Long‐term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib

High-grade B-cell lymphomas with TdT expression: a diagnostic and classification dilemma

Aberrant Activation of the Hedgehog Signaling Pathway in Malignant Hematological Neoplasms

ETNK1 mutation occurs in a wide spectrum of myeloid neoplasms and is not specific for atypical chronic myeloid leukemia

Mantle cell lymphoma involving tonsils: a clinicopathologic study of 83 cases

Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia

Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) ‐ outcomes and mutation profile from venetoclax resistant MCL patients

Ibrutinib–rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial

Validation of a 12‐color flow cytometry assay for acute myeloid leukemia minimal/measurable residual disease detection

CD30 expression is frequently decreased in relapsed classic Hodgkin lymphoma after anti‐CD30 CAR T‐cell therapy

Prevalence and Clinical Implications of Epstein―Barr Virus Infection in De Novo Diffuse Large B-Cell Lymphoma in Western Countries

Genomic and clinical characterization of B/T mixed phenotype acute leukemia reveals recurrent features and T‐ALL like mutations

Acquired WT1 mutations contribute to relapse of NPM1-mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplant

Mantle cell lymphoma with chronic lymphocytic leukemia-like features: a diagnostic mimic and pitfall

EZH2 expression is associated with inferior overall survival in mantle cell lymphoma

Acute Myeloid Leukemia and Myelodysplastic Syndromes After Radiation Therapy Are Similar to De Novo Disease and Differ From Other Therapy-Related Myeloid Neoplasms

Clinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology group

Myelodysplastic syndromes with no somatic mutations detected by next‐generation sequencing display similar features to myelodysplastic syndromes with detectable mutations

Clinical, immunophenotypic and genomic findings of NK lymphoblastic leukemia: a study from the Bone Marrow Pathology Group

Chronic myeloid neoplasms harboring concomitant mutations in myeloproliferative neoplasm driver genes (JAK2/MPL/CALR) and SF3B1

Suchergebnisse filtern